Form 10-Q BrightSpring Health Serv For: Sep 30
http://archive.fast-edgar.com/20251028/AN22222EZZ2RVTZ222JV2ZYMVJ7WEZ22X272
Filed on: October 28, 2025
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Crypto News Today: Another Iran Shock Could Slam Bitcoin and Ethereum as AlphaPepe Enters the Next Shiba Inu Race
- Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 S
- TAGRISSO® (osimertinib) plus savolitinib reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share